Targeting PCSK9 in Liver Cancer Cells Triggers Metabolic Exhaustion and Cell Death by Ferroptosis

被引:16
作者
Alannan, Malak [1 ]
Fatrouni, Hala [1 ]
Trezeguet, Veronique [1 ]
Dittrich-Domergue, Franziska [2 ]
Moreau, Patrick [2 ]
Siegfried, Geraldine [1 ]
Liet, Benjamin [1 ]
Khatib, Abdel-Majid [1 ]
Grosset, Christophe F. [1 ]
Badran, Bassam [3 ]
Fayyad-Kazan, Hussein [3 ]
Merched, Aksam J. [1 ]
机构
[1] Univ Bordeaux, Bordeaux Inst Oncol BRIC, Inserm U1312, F-33000 Bordeaux, France
[2] Univ Bordeaux, UMR 5200, CNRS, Lab Biogenese Membranaire, F-33140 Villenave Dornon, France
[3] Lebanese Univ, Fac Sci 1, Lab Canc Biol & Mol Immunol, Beirut 90656, Lebanon
关键词
PCSK9; ferroptosis; hepatocellular carcinoma; hepatoblastoma; lipid metabolism; PATHWAYS; PROTECTS;
D O I
10.3390/cells12010062
中图分类号
Q2 [细胞生物学];
学科分类号
071009 ; 090102 ;
摘要
Deregulated lipid metabolism is a common feature of liver cancers needed to sustain tumor cell growth and survival. We aim at taking advantage of this vulnerability and rewiring the oncogenic metabolic hub by targeting the key metabolic player pro-protein convertase subtilisin/kexin type 9 (PCSK9). We assessed the effect of PCSK9 inhibition using the three hepatoma cell lines Huh6, Huh7 and HepG2 and validated the results using the zebrafish in vivo model. PCSK9 deficiency led to strong inhibition of cell proliferation in all cell lines. At the lipid metabolic level, PCSK9 inhibition was translated by an increase in intracellular neutral lipids, phospholipids and polyunsaturated fatty acids as well as a higher accumulation of lipid hydroperoxide. Molecular signaling analysis involved the disruption of the sequestome 1/Kelch-like ECH-associated protein 1/nuclear factor erythroid 2-related factor 2 (p62/Keap1/Nrf2) antioxidative axis, leading to ferroptosis, for which morphological features were confirmed by electron and confocal microscopies. The anti-tumoral effects of PCSK9 deficiency were validated using xenograft experiments in zebrafish. The inhibition of PCSK9 was effective in disrupting the oncometabolic process, inducing metabolic exhaustion and enhancing the vulnerability of cancer cells to iron-triggered lipid peroxidation. We provide strong evidence supporting the drug repositioning of anti-PCSK9 approaches to treat liver cancers.
引用
收藏
页数:17
相关论文
共 27 条
  • [1] Targeting Lipid Metabolism in Liver Cancer
    Alannan, Malak
    Fayyad-Kazan, Hussein
    Trezeguet, Veronique
    Merched, Aksam
    [J]. BIOCHEMISTRY, 2020, 59 (41) : 3951 - 3964
  • [2] Decreased PCSK9 expression in human hepatocellular carcinoma
    Bhat, Mamatha
    Skill, Nicolas
    Marcus, Victoria
    Deschenes, Marc
    Tan, Xianming
    Bouteaud, Jeanne
    Negi, Sarita
    Awan, Zuhier
    Aikin, Reid
    Kwan, Janet
    Amre, Ramila
    Tabaries, Sebastien
    Hassanain, Mazen
    Seidah, Nabil G.
    Maluccio, Mary
    Siegel, Peter
    Metrakos, Peter
    [J]. BMC GASTROENTEROLOGY, 2015, 15
  • [3] Ferroptosis: An Iron-Dependent Form of Nonapoptotic Cell Death
    Dixon, Scott J.
    Lemberg, Kathryn M.
    Lamprecht, Michael R.
    Skouta, Rachid
    Zaitsev, Eleina M.
    Gleason, Caroline E.
    Patel, Darpan N.
    Bauer, Andras J.
    Cantley, Alexandra M.
    Yang, Wan Seok
    Morrison, Barclay, III
    Stockwell, Brent R.
    [J]. CELL, 2012, 149 (05) : 1060 - 1072
  • [4] Three Arabidopsis Fatty Acyl-Coenzyme A Reductases, FAR1, FAR4, and FAR5, Generate Primary Fatty Alcohols Associated with Suberin Deposition
    Domergue, Frederic
    Vishwanath, Sollapura J.
    Joubes, Jerome
    Ono, Jasmine
    Lee, Jennifer A.
    Bourdon, Matthieu
    Alhattab, Reem
    Lowe, Christine
    Pascal, Stephanie
    Lessire, Rene
    Rowland, Owen
    [J]. PLANT PHYSIOLOGY, 2010, 153 (04) : 1539 - 1554
  • [5] Cancer Chemoprevention Mechanisms Mediated Through the Keap1-Nrf2 Pathway
    Hayes, John D.
    McMahon, Michael
    Chowdhry, Sudhir
    Dinkova-Kostova, Albena T.
    [J]. ANTIOXIDANTS & REDOX SIGNALING, 2010, 13 (11) : 1713 - 1748
  • [6] New insights into diagnosis and therapeutic options for proliferative hepatoblastoma
    Hooks, Katarzyna B.
    Audoux, Jerome
    Fazli, Helena
    Lesjean, Sarah
    Ernault, Tony
    Dugot-Senant, Nathalie
    Leste-Lasserre, Thierry
    Hagedorn, Martin
    Rousseau, Benoit
    Danet, Coralie
    Branchereau, Sophie
    Brugieres, Laurence
    Taque, Sophie
    Guettier, Catherine
    Fabre, Monique
    Rullier, Anne
    Buendia, Marie-Annick
    Commes, Therese
    Grosset, Christophe F.
    Raymond, Anne-Aurelie
    [J]. HEPATOLOGY, 2018, 68 (01) : 89 - 102
  • [7] Kagan VE, 2017, NAT CHEM BIOL, V13, P81, DOI [10.1038/NCHEMBIO.2238, 10.1038/nchembio.2238]
  • [8] Inclisiran: First Approval
    Lamb, Yvette N.
    [J]. DRUGS, 2021, 81 (03) : 389 - 395
  • [9] Inhibition of PCSK9 potentiates immune checkpoint therapy for cancer
    Liu, Xinjian
    Bao, Xuhui
    Hu, Mengjie
    Chang, Hanman
    Jiao, Meng
    Cheng, Jin
    Xie, Liyi
    Huang, Qian
    Li, Fang
    Li, Chuan-Yuan
    [J]. NATURE, 2020, 588 (7839) : 693 - +
  • [10] The retinoblastoma (Rb) protein regulates ferroptosis induced by sorafenib in human hepatocellular carcinoma cells
    Louandre, Christophe
    Marcq, Ingrid
    Bouhlal, Hicham
    Lachaier, Emma
    Godin, Corinne
    Saidak, Zuzana
    Francois, Catherine
    Chatelain, Denis
    Debuysscher, Veronique
    Barbare, Jean-Claude
    Chauffert, Bruno
    Galmiche, Antoine
    [J]. CANCER LETTERS, 2015, 356 (02) : 971 - 977